Immunocytochemistry with a monoclonal antibody against the GABAA/benzodiazepine receptor showed labeled axo-dendritic synapses in the anteroventral cochlear nucleus. In the dorsal cochlear nucleus, label was seen apposing both axo-somatic and axo-dendritic terminals. The results suggest a heterogeneous distribution of GABA receptors, together with a possible segregation of receptor subtypes between somata and dendrites in certain neurons. The presence of cytoplasmic labeling in some neurons might reflect a higher receptor turnover rate in these neurons.
Immunocytochemistry with a monoclonal antibody against the GABAA/benzodiazepine receptor showed labeled axo-dendritic synapses in the anteroventral cochlear nucleus. In the dorsal cochlear nucleus, label was seen apposing both axo-somatic and axo-dendritic terminals. The results suggest a heterogeneous distribution of GABA receptors, together with a possible segregation of receptor subtypes between somata and dendrites in certain neurons. The presence of cytoplasmic labeling in some neurons might reflect a higher receptor turnover rate in these neurons.
Many studies indicate that 3,-aminobutyric acid (GABA) is an important neurotransmitter mediating inhibition in the cochlear nucleus (CN) (for review see refs. 7, 58). GABA and glutamic acid decarboxylase (GAD) levels are high in the cochlear nucleus 12"ls'l~'62, particularly in the dorsal CN 15. GABA and GAD have been localized immunocytochemically in cells, fibers and terminals in the CN i'27'29'31'32'38'44'52'61. GABA is released in a calcium-dependent manner from CN slices t~' 56 and uptake c,,f tritiated GABA has been demonstrated in the CN 34'42. l,antophoretic application of GABA inhibits neuronal firing in the CN s'24'25'62 and this effect is abolished with the GABA antagonist bicuculline 25.
Receptor binding sites for GABA are present in the CN, as binding of the GABA agonist muscimol has been demonstrated autoradiographically in the CN at the light microscopic level 1334. However, a comparison of the distribution of the muscimol binding with that of the distribution of GABA and GAD-like immunoreactivity in the CN shows some degree of mismatch. In the central portions of the ventral CN, where'there is a high density of GABA-immunoreactive terminals, a low density of [3H]muscimol binding sites was observed. Furthermore, recent findings indicate that not only is GABA colocalized with glycine in CN cells, fibers and terminals 3°" 57 (personal observations), but glycine receptor immunoreactivity is seen apposing GABA-immunoreactive terminals in the CN 3°. These results raise questions as to the correlation between GABA receptors and GABAergic terminals. With the recent development of monoclonal antibodies to the GABAg/benzodiazepine (BDZ) receptor complex ~°'3~'4°'55, it is now possible to study the distribution of this receptor complex with great sensitivity and resolution. For this study, we have used a monoclohal antibody against the GABAA/BDZ receptor s5 to investigate, at both the light and electron microscopic level, the distribution of GABAA/BDZ receptor-like immunoreactivity (Ll) in the CN.
Twelve adult guinea pigs were heavily anesthetized with chloral hydrate and perfused intravascularly with saline followed by a fixative containing 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M cacodylate bufter. The brainstem was removed, placed in the same fixative for 4 h at 4 °C and washed overnight in cold buffer. Sections through the CN of 50 ~tm thickness, obtained using an oscillating tissue slicer (Vibratome), were incubated for 72 h in the monoclonal antibody 62-3G11°'55 diluted 1:100 in phosphate-buffered saline (PBS). This antibody has been shown to react with a 57,000 M r (fl) subunit of the GABAA/BDZ receptor complex in immunoblots, and its characteristics and specificity have been described hi detail ss. The avidinbiotin-peroxidase complex (ABC) technique of Hsu et al. 19 (Vectastain kit, Vector Labs) was used to visualize the immunoreaction product, with diaminobenzidine as the chromogen. As a control for the specificity of this method, alternate sections were incubated either in non-immune mouse serum or in PBS substituted for the primary antibody. Sections for light microscopy (LM) were mounted onto slides, allowed to dry overnight, coverslipped and observed with a Leitz Dialux photomicroscope equipped with differential interference contrast optics. Sections for electron microscopy (EM) were postfixed in a mixture of 1% osmium tetroxide and 1.5% potassium ferricyanide, dehydrated in graded ethanols and embedded in EMbed 812 (EMSciences). Sections of 75-80 nm thickness of the anteroventral (AVCN) and dorsal (DCN) cochlear nucleus were observed without uranyl acetate or lead citrate counterstaining, using a JEOL EM-1200 electron microscope.
Immunostaining was not observed, either at the LM or EM levels, in the control sections of which the incubation in primary antibody was omitted. As uranyl acetate and lead citrate were not used to counterstain ultrathin sections, the synaptic densities were undetectable electron microscopically. Thus, it was assumed that the labeling observed in the experimental tissue was related to the presence of specific immunolabeling.
Apart from some scattered granule cells in the granule cell layer, no immunostaining was evident in the VCN (AVCN and PVCN) at the LM level after incubation with the 62-3G1 antibody (Fig. la) . In contrast, the DCN showed intense GABAA/BDZ receptor-LI, particularly in the superficial (molecular and fusiform) layers. Me- dium-and small-sized cell bodies in these layers were labeled (Fig. lb,c) , as were fusiform cell bodies (Fig. lc) .
Immunoreactive dendritic profiles were also abundant (Fig. lc) .
Immunostaining was evident at the EM level in the rostral AVCN, despite its lack of visibility at thc LM level. GABAA/BDZ receptor-LI was observed in medium and small caliber dendrites, postsynaptic to terminals containing oval/pleomorphic vesicles (Fig. 2a,b) and, less frequently, in primary dendritic trunks (Fig. 2c) . No immunoreactivity was seen apposing terminals on spherical/bushy cell bodies (Fig. 2a) , despite the fact that these somata have been shown to receive a significant number of GABA-iike immunoreactive terminals a°'31"38"44"5°'52'61. In the DCN, however, GABAA/BDZ receptor-LI apposed both axo-somatic (Fig. 3a) and axo-dendritic (Fig.  3b,c) terminals on fusiform cells. Some of the medium and small cells in the molecular and fusiform cell layers als0 had GABAA/BDZ receptor-LI apposing terminals on both somata and dendrites. While most terminals apposing GABAA/BDZ receptor immunolabel contained oval/pleomorphic vesicles, some possessed flattened vesicles (Fig. 2c) . Occasionally, presynaptic localization of the GABAA/BDZ receptor was observed both in DCN (Fig. 3a) and AVCN. In both subdivisions, the immunolabeling was always associated with the cytoplasmic side of the junctional membrane (Figs. 2a,b,c and 3a,b,c) . However, the labeling was not restricted to synaptic membranes. Intense cytoplasmic labeling was also seen deep within fusiform and small cell bodies in the DCN (Figs. lb,c and 3a) , as well as in dendritic profiles in both AVCN (Fig. 2b) and DCN (Fig. 3c) . The immunolabei was usually associated with cytoskeletal structures and mitochondrial membranes (Figs. 2b and 3a,c) . Some granule cell bodies and dendrites also contained abundant cytoplasmic staining. No label was ever found in glial cells.
The present study demonstrates the' existence of A synapse on a fusiform cell body (3a,fc) shows post-and presynaptic immunoreaction product (3a, arrowheads), in the fusiform (3b) and molecular (3c) layers, terminals contacting dendrites appose postsynaptic immunoreactivity (3b, 'a' ~md 'b'. 3c, arrowheads). Cytoplasmic labeling is also obvious (3a, 3c). In 3b, synapse 'a', which is closer to the cutting surfacc, is more intensely stained than synapse 'b' (arrowheads). Non eounterstained material. Scale bars 3a:125 nm. 3b:500 nm. 3c:201) nm. Several possibilities exist to explain the finding of a heterogeneous localization of the GABAA/BDZ receptor-LI in the CN and the mismatch with the distribution of GABA-LI terminals. It is possible that the structure of GABAA/BDZ receptors on spherical/bushy cell bodies is different than those on their dendrites, or in DCN cell bodies and dendrites. As such they would not be recognized by the monoclonal antibody used in this study. 62-3G1 recognizes an epitope in the 57,000 M r ~) subunit (GABA/muscimol binding site) of the receptor complex ~°'55. In this regard, our results correlate well with the distribution of [3H]muscimol binding sites in the CN observed in other studies 13'~4. However, the GA-BAA/BDZ receptor complex has been shown in other areas to exhibit considerable structural heterogeneity as demonstrated by differences in ligand binding, photoafo finity and immunoaffinity labeling properties 21'a3,3s'36. Molecular heterogeneity has also been described using recombinant DNA techniques, where the different polypeptide subunits of the receptor complex seem to exhibit important variations in their respective primary structures 4'22'36'4t. Furthermore, in situ hybridization studies indicate a differential distribution in the CNS of the mRNAs coding for different subunits of the GABAA/ BDZ receptor complex 22'43'46. These results suggest that a particular antibody to the GABAA/BDZ receptor might not recognize all its forms. How these possible structural differences may affect the binding properties of the receptor (muscimol binding, for exampte) must be addressed in the future.
The subcellular localization of GABAA/BDZ receptor-LI (see Figs. 2 and 3) suggests that the antigenic determinant recognized by the antibody resides either in the cytoplasmic or in the intramembrane domain of the ,6 subunit. This means that if there are structural variations in the GABA~, receptors of the CN (see abo ~.'e), this variation resides, at least, in this region(s) of the f! subunit. The use of antibodies against other epitopes of the GABAA/BDZ receptor 37'4s would be helpful to address the extension and location of these structural heterogeneities, whose functional role, at present, is not clear.
Another possible explanation for our observations of receptor heterogeneity could be that there are GABAergic terminals not apposed by postsynaptic GABAA/ BDZ receptors, but rather by GABA a receptors. GABAa receptors are believed to be mainly presynaptic 5. However their involvement in postsynaptic inhibition has also been proposed 5"~l'28. In the CN, Baclofen, an agonist of GABA at GABAa receptors, reduces tone-evoked activity 7. Although this effect has been linked to inhibition of the release of glutamate and aspartate through a presynaptic GABAn receptor 7, the presence, distribution and function of postsynaptic GABAn receptors on CN neurons needs to be determined. The availability of GABA antagonists at GABAa receptors ~I and the recent development of monoclonal antibodies directed against Baclofen ~7 will help to address the question of GABA n receptor localization in the CN.
Regardless of the type (GABAA or GABAa), our results suggest that different subpopulations of GABA receptors could be segregated to different receptive regions (somata and dendrites) in some neurons. This would raise questions regarding the possible functions of receptor segregation in terms of auditory signal processing. Also, a differential receptor distribution between somatic and dendritic synapses might be important in phenomena involving specific recognition between cells. Our observation of GABAA/BDZ label presynaptically and its significance also adds to questions deserving future study.
GABAA/BDZ receptor-LI was observed in the cytoplasm of fusiform and small neurons in the DCN.
1 Adams, J.C. and Mugnaini, E., Patterns of GAD immunostaining in the feline cochlear nuclear complex studied with silver enhancement and electron microscopy, Intracellular labeling has been previously described using this antibody and other anti GABAA receptor monoclonal antibodies in different regions of the brain of various species 1°'!8"23"37"48"63. At the EM level, the cytoplasmic label appeared within the perikarya and dendrites of DCN fusiform cells as well as in some granule cells both in DCN and VCN. This labeling is only seen in cells that also have GABAA/BDZ receptor-LI apposing terminals. A likely explanation for this finding, also observed in other receptors and neuronal surface proteins 2°' 39"47"49"51, is that it might represent the receptor undergoing synthesis or degradation. The observation that some neuronal types display more intracellular immunoreactivity than others might reflect different receptor turnover rates. It should be noted that an internal pool for GABAA/BDZ receptors has been described in cultured neurons, using biochemical techniques 9.
The results of the present study provide further evidence of GABA receptor heterogeneity in the central nervous ~'.ystem, with the additional intriguing suggestion of differential localization and segregation of GABA receptor types between the soma and dendrites within individual neurons. The functional implications of this receptor heterogeneity for the processing of auditory information remains to be determined.
